Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity

NCT07564986 | Completed

• 1 other identifier: 2024-KAEK-11
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate whether a specific protein in the blood, called resistin, can help doctors predict how much dangerous internal fat a patient will lose following weight loss surgery. Sleeve gastrectomy is a common and effective procedure that reduces the stomach's size to help patients lose weight and improve their metabolic health. Beyond just losing weight, it is vital to reduce visceral fat-the fat stored around internal organs-which is closely linked to inflammation and conditions like Type 2 Diabetes. Resistin is a marker known to contribute to insulin resistance and is typically higher in individuals with significant abdominal fat. By measuring resistin levels before surgery, we want to determine if this protein can serve as a guide to predict a patient's internal fat loss and overall metabolic recovery. Ultimately, this research could help healthcare providers better understand the hormonal changes that occur during weight loss and identify which patients may experience the most significant health improvements after the procedure.

Conditions

Morbid Obesity Requiring Bariatric Surgery

Keywords

Resistin; morbid obesity; bariatric surgery; sleeve gastrectomy

Outcome Measures

Primary Outcomes (1)

• Change in body mass index at 8 months

  8 months after surgery

Secondary Outcomes (2)

• Change in visseral fat at 8 months

  8 months after surgery

• Change in basal metabolic rate at 8 months

  8 months after surgery

Study Arms (1)

Sleeve Gastrectomy Patients

Patients who meet inclusion criteria for the study undergoing sleeve gastrectomy

Procedure: Laparoscopic Sleeve Gastrectomy

Interventions

Laparoscopic Sleeve Gastrectomy PROCEDURE

Laparoscopic Sleeve Gastrectomy

Sleeve Gastrectomy Patients

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients applying to Başakşehir Çam Sakura City Hospital General Surgery Clinic for bariatric surgery

You may qualify if:

• Patients aged 18 to 75
• International Classification of Diseases (ICD) code E66 diagnosis (obesity)
• Patients who have given consent for sleeve gastrectomy
• Patients who are suitable for general anesthesia

You may not qualify if:

• Patients who did not give consent to be included in the study
• Patients who are scheduled for surgery other than sleeve gastrectomy

Sponsors & Collaborators

• Sercan YUKSEL, MD: lead

Study Sites (1)

Basaksehir Cam and Sakura City Hospital

Istanbul, Basaksehir, 34480, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood will be centrifuged and serum will be stored separately in eppendorf tubes.

MeSH Terms

Conditions

Obesity, Morbid

Condition Hierarchy (Ancestors)

Obesity; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: April 27, 2026
• First Posted: May 4, 2026
• Study Start: April 1, 2025
• Primary Completion: April 27, 2026
• Study Completion: April 27, 2026
• Last Updated: May 4, 2026

Record last verified: 2026-04

Locations

TU (1)